Oct 7 (Reuters) – Glaukos said on Wednesday patients treated with its late-stage eye disease therapy maintained improvements in vision and corneal shape three years after a single treatment for
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)